

Primary Care POC Diagnostics Market Forecasts to 2034 – Global Analysis By Product (Urinalysis, Ambulatory Chemistry, Infectious Diseases Testing Kits and Other Products), Technology, Sample Type, Distribution Channel, End User and By Geography

<https://marketpublishers.com/r/PDC48E3A3B69EN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: PDC48E3A3B69EN

Abstracts

According to Statistics MRC, the Global Primary Care POC Diagnostics Market is accounted for \$21.3 billion in 2026 and is expected to reach \$40.9 billion by 2034 growing at a CAGR of 8.5% during the forecast period. Primary Care Point-of-Care (POC) Diagnostics are diagnostic tools and tests used in primary care settings that enable medical professionals to get test results right away in close proximity to the patient. These tests are carried out at the point of patient care, or in close proximity to it, providing quick and easy access to diagnostic data for prompt clinical decision-making. During patient consultations, these tests enable healthcare practitioners to make prompt clinical judgments since they yield data quickly often in a matter of minutes. Maintaining high-quality testing and dependable findings in primary care settings requires POC diagnostics to ensure accuracy, dependability, and compliance with regulatory criteria.

According to the World Health Organization (WHO), approximately 354 million people globally are hepatitis B or C positive, and diagnosis and treatment are unavailable. The WHO aims to control and reduce new infections by 90% and deaths by 65% by 2030.

Market Dynamics:

Driver:

Demand for point-of-care solutions in healthcare settings

The availability of rapid testing at the point of patient care is encouraged by the need for point-of-care solutions. This allows for quick clinical choices and timely treatments during patient consultations in primary care by providing quick access to diagnostic information. This diagnostics speeds up test results considerably by removing the requirement to ship samples to centralized laboratories. This quick access to information facilitates more effective workflows in primary care settings and speeds up patient care, especially for urgent situations which further enhance the growth of the market.

Restraint:

Price pressure as a result of reduced reimbursement and financial limitations

Lower reimbursements or reimbursement for point-of-care (POC) diagnostic tests may result in higher expenses for patients or healthcare institutions. This may result in a decrease in the cost or availability of certain tests, particularly for smaller primary care clinics or underprivileged communities. Additionally, financial restrictions may force healthcare institutions to choose less expensive, lower-quality point-of-care (POC) diagnostic tests, which might compromise test range, accuracy, or reliability with stunt in the growth of the market.

Opportunity:

Demand for immediate diagnostic results

Immediate outcomes' main objective is to speed up clinical decision-making in primary care settings. Point-of-care (POC) diagnostics allow medical professionals to quickly and intelligently decide how best to treat patients at a single visit. These diagnostics drastically shorten the time it takes to get test results by doing away with the requirement for centralized laboratories. Thus, quick information availability guarantees quick interventions and speeds up the diagnostic procedure creating wide range of opportunities for the market.

Threat:

Lack of accuracy and reliability

Results from primary care point-of-care diagnostic tests that are inaccurate or untrustworthy may result in misdiagnoses, ineffective therapies, or a delay in essential

actions. This might have a detrimental effect on health outcomes and jeopardize patient safety. When primary care POC diagnostic tests with a track record of errors are used by healthcare practitioners or institutions, patients may become dissatisfied or lose faith in them. Patient trust in their medical care and satisfaction may be impacted by this.

Covid-19 Impact

Demand for rapid point-of-care (POC) diagnostics surged in response to the need for quick and easily accessible SARS-CoV-2 testing. In primary care settings, procedures such as molecular POC testing and lateral flow assays (LFAs) have become indispensable for rapid COVID-19 identification. Moreover, telehealth services and remote testing choices proliferated in an attempt to reduce exposure and preserve social isolation. Thus a few POC tests were modified for use in telemedicine so that patients may take tests at home under the supervision of a remote provider.

The ambulatory chemistry segment is expected to be the largest during the forecast period

The ambulatory chemistry segment is estimated to have a lucrative growth, as the term 'ambulatory chemistry' describes the practice of doing biochemical analyses or chemistry tests outside of a conventional laboratory environment, usually at point-of-care (POC) or ambulatory care settings. The principal objective is to expedite and accurately collect basic biochemistry test findings to facilitate prompt clinical decision-making during patient consultations in ambulatory or primary care settings. When biochemical tests are performed in ambulatory settings, patients can visit less centralized facilities for routine testing, which can save time and facilitate diagnosis.

The lateral flow assays (LFAs) segment is expected to have the highest CAGR during the forecast period

The lateral flow assays (LFAs) segment is anticipated to witness the highest CAGR growth during the forecast period, because these tests are easy to use, quick to complete, and reasonably priced. They are intended to find out whether a certain analyte is present in biological samples like blood, urine, saliva, or other body fluids. These tests are appropriate for use in primary care or point-of-care (POC) settings where prompt findings are essential for making timely clinical choices thus encourage the growth of the market.

Region with largest share:

North America is projected to hold the largest market share during the forecast period because so many primary care facilities in the United States use POC equipment and the significant portion of this regional market has also been linked to the existence of significant firms in the nation providing goods and services for primary settings. Healthcare providers are being urged by the Centers for Medicare & Medicaid Services to start patient engagement initiatives. The market is being driven by this as well as the availability of financing for healthcare R&D by academic institutions boost the growth of the market in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the availability of several cutting-edge and creative POC diagnostic solutions, the Asia-Pacific market is comparatively more developed than the rest of the globe. Another important growth driver is the increasing demand for these solutions in primary home healthcare and supported healthcare settings. This is explained by the fact that more businesses are taking use of the unrealized potential in the area. Furthermore, it is anticipated that the Asia Pacific market would develop as a result of rising public awareness of the need of early illness diagnosis to increase patient survival rates.

Key players in the market

Some of the key players profiled in the Primary Care POC Diagnostics Market include BD Biosciences, Roche Diagnostics, Abbott Laboratories, bioMérieux, Instrumentation Laboratory, Quidel Corporation, Danaher Corporation, Siemens Healthcare, Agilent Technologies, Decode Genetics, Axis-Shield, Becton Dickinson, Nova Biomedical, Trividia Health, Inc., OraSure Technologies, Inc. and Abaxis

Key Developments:

In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

In November 2023, BD a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a memorandum of understanding (MOU) for a joint effort to combat tuberculosis (TB)

In September 2023, bbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Products Covered:

Urinalysis

Ambulatory Chemistry

Infectious Diseases Testing Kits

Lipid Testing

Glucose Monitoring Devices

Hematology Testing Devices

Blood Gas/Electrolytes

Hb1Ac Testing

Autoimmune Disease

Coagulation Monitoring Devices

Cardiac Markers

Thyroid Stimulating Hormone Devices

Drug Abuse Testing

Pregnancy & Fertility Testing Products

Other Products

Technologies Covered:

Immunoassays

Lateral Flow Assays (LFAs)

Molecular Diagnostics

Clinical Chemistry

Electrochemical & Biosensor Technologies

Other Technologies

Sample Types Covered:

Urine

Blood

Nasal & Oropharyngeal Swabs

Other Sample Types

Distribution Channels Covered:

Pharmacies

Retail clinics

E-comm. Platforms

Other Distribution Channels

End Users Covered:

Home Care & Self Testing

Hospitals

Critical Care Centers & Urgent care centers

Ambulatory Care Facilities

Clinical Laboratories

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment

Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Technology Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL PRIMARY CARE POC DIAGNOSTICS MARKET, BY PRODUCT

- 5.1 Introduction
- 5.2 Urinalysis
- 5.3 Ambulatory Chemistry
- 5.4 Infectious Diseases Testing Kits
- 5.5 Lipid Testing
- 5.6 Glucose Monitoring Devices
- 5.7 Hematology Testing Devices
- 5.8 Blood Gas/Electrolytes
- 5.9 Hb1Ac Testing
- 5.10 Autoimmune Disease
- 5.11 Coagulation Monitoring Devices
- 5.12 Cardiac Markers
- 5.13 Thyroid Stimulating Hormone Devices
- 5.14 Drug Abuse Testing
- 5.15 Pregnancy & Fertility Testing Products
- 5.16 Other Products

6 GLOBAL PRIMARY CARE POC DIAGNOSTICS MARKET, BY TECHNOLOGY

- 6.1 Introduction
- 6.2 Immunoassays
- 6.3 Lateral Flow Assays (LFAs)
- 6.4 Molecular Diagnostics
- 6.5 Clinical Chemistry
- 6.6 Electrochemical & Biosensor Technologies
- 6.7 Other Technologies

7 GLOBAL PRIMARY CARE POC DIAGNOSTICS MARKET, BY SAMPLE TYPE

- 7.1 Introduction
- 7.2 Urine
- 7.3 Blood
- 7.4 Nasal & Oropharyngeal Swabs
- 7.5 Other Sample Types

8 GLOBAL PRIMARY CARE POC DIAGNOSTICS MARKET, BY DISTRIBUTION

CHANNEL

- 8.1 Introduction
- 8.2 Pharmacies
- 8.3 Retail clinics
- 8.4 E-comm. Platforms
- 8.5 Other Distribution Channels

9 GLOBAL PRIMARY CARE POC DIAGNOSTICS MARKET, BY END USER

- 9.1 Introduction
- 9.2 Home Care & Self Testing
- 9.3 Hospitals
- 9.4 Critical Care Centers & Urgent care centers
- 9.5 Ambulatory Care Facilities
- 9.6 Clinical Laboratories

10 GLOBAL PRIMARY CARE POC DIAGNOSTICS MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea
 - 10.4.7 Rest of Asia Pacific

- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa
 - 10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 BD Biosciences
- 12.2 Roche Diagnostics
- 12.3 Abbott Laboratories
- 12.4 bioMerieux
- 12.5 Instrumentation Laboratory
- 12.6 Quidel Corporation
- 12.7 Danaher Corporation
- 12.8 Siemens Healthcare
- 12.9 Agilent Technologies
- 12.10 Decode Genetics
- 12.11 Axis-Shield
- 12.12 Becton Dickinson
- 12.13 Nova Biomedical
- 12.14 Trividia Health, Inc.
- 12.15 OraSure Technologies, Inc.
- 12.16 Abaxis

List Of Tables

LIST OF TABLES

Table 1 Global Primary Care POC Diagnostics Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Primary Care POC Diagnostics Market Outlook, By Product (2023-2034) (\$MN)

Table 3 Global Primary Care POC Diagnostics Market Outlook, By Urinalysis (2023-2034) (\$MN)

Table 4 Global Primary Care POC Diagnostics Market Outlook, By Ambulatory Chemistry (2023-2034) (\$MN)

Table 5 Global Primary Care POC Diagnostics Market Outlook, By Infectious Diseases Testing Kits (2023-2034) (\$MN)

Table 6 Global Primary Care POC Diagnostics Market Outlook, By Lipid Testing (2023-2034) (\$MN)

Table 7 Global Primary Care POC Diagnostics Market Outlook, By Glucose Monitoring Devices (2023-2034) (\$MN)

Table 8 Global Primary Care POC Diagnostics Market Outlook, By Hematology Testing Devices (2023-2034) (\$MN)

Table 9 Global Primary Care POC Diagnostics Market Outlook, By Blood Gas/Electrolytes (2023-2034) (\$MN)

Table 10 Global Primary Care POC Diagnostics Market Outlook, By Hb1Ac Testing (2023-2034) (\$MN)

Table 11 Global Primary Care POC Diagnostics Market Outlook, By Autoimmune Disease (2023-2034) (\$MN)

Table 12 Global Primary Care POC Diagnostics Market Outlook, By Coagulation Monitoring Devices (2023-2034) (\$MN)

Table 13 Global Primary Care POC Diagnostics Market Outlook, By Cardiac Markers (2023-2034) (\$MN)

Table 14 Global Primary Care POC Diagnostics Market Outlook, By Thyroid Stimulating Hormone Devices (2023-2034) (\$MN)

Table 15 Global Primary Care POC Diagnostics Market Outlook, By Drug Abuse Testing (2023-2034) (\$MN)

Table 16 Global Primary Care POC Diagnostics Market Outlook, By Pregnancy & Fertility Testing Products (2023-2034) (\$MN)

Table 17 Global Primary Care POC Diagnostics Market Outlook, By Other Products (2023-2034) (\$MN)

Table 18 Global Primary Care POC Diagnostics Market Outlook, By Technology

(2023-2034) (\$MN)

Table 19 Global Primary Care POC Diagnostics Market Outlook, By Immunoassays (2023-2034) (\$MN)

Table 20 Global Primary Care POC Diagnostics Market Outlook, By Lateral Flow Assays (LFAs) (2023-2034) (\$MN)

Table 21 Global Primary Care POC Diagnostics Market Outlook, By Molecular Diagnostics (2023-2034) (\$MN)

Table 22 Global Primary Care POC Diagnostics Market Outlook, By Clinical Chemistry (2023-2034) (\$MN)

Table 23 Global Primary Care POC Diagnostics Market Outlook, By Electrochemical & Biosensor Technologies (2023-2034) (\$MN)

Table 24 Global Primary Care POC Diagnostics Market Outlook, By Other Technologies (2023-2034) (\$MN)

Table 25 Global Primary Care POC Diagnostics Market Outlook, By Sample Type (2023-2034) (\$MN)

Table 26 Global Primary Care POC Diagnostics Market Outlook, By Urine (2023-2034) (\$MN)

Table 27 Global Primary Care POC Diagnostics Market Outlook, By Blood (2023-2034) (\$MN)

Table 28 Global Primary Care POC Diagnostics Market Outlook, By Nasal & Oropharyngeal Swabs (2023-2034) (\$MN)

Table 29 Global Primary Care POC Diagnostics Market Outlook, By Other Sample Types (2023-2034) (\$MN)

Table 30 Global Primary Care POC Diagnostics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 31 Global Primary Care POC Diagnostics Market Outlook, By Pharmacies (2023-2034) (\$MN)

Table 32 Global Primary Care POC Diagnostics Market Outlook, By Retail clinics (2023-2034) (\$MN)

Table 33 Global Primary Care POC Diagnostics Market Outlook, By E-comm. Platforms (2023-2034) (\$MN)

Table 34 Global Primary Care POC Diagnostics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

Table 35 Global Primary Care POC Diagnostics Market Outlook, By End User (2023-2034) (\$MN)

Table 36 Global Primary Care POC Diagnostics Market Outlook, By Home Care & Self Testing (2023-2034) (\$MN)

Table 37 Global Primary Care POC Diagnostics Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 38 Global Primary Care POC Diagnostics Market Outlook, By Critical Care Centers & Urgent care centers (2023-2034) (\$MN)

Table 39 Global Primary Care POC Diagnostics Market Outlook, By Ambulatory Care Facilities (2023-2034) (\$MN)

Table 40 Global Primary Care POC Diagnostics Market Outlook, By Clinical Laboratories (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Primary Care POC Diagnostics Market Forecasts to 2034 – Global Analysis By Product (Urinalysis, Ambulatory Chemistry, Infectious Diseases Testing Kits and Other Products), Technology, Sample Type, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/PDC48E3A3B69EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PDC48E3A3B69EN.html>